Grow more relationships

Grow more relationships

Newark, New Castle, USA, June 15, 2023 (GLOBE NEWSWIRE) — Global Market Analysis choroideremia treatment market was conducted by Growth Plus Reports in 2022 and was rated at $3.5 billion. The market should achieve an income CAGR of 5.3% reach $5.5 billion by 2031.

The analysis of the global Choroideremia Treatment market indicates that over the forecast period, the revenue share is likely to increase significantly. The choroideremia treatment market encompasses pharmaceuticals, therapies, and interventions used to manage and treat choroideremia, a rare genetic eye disease that causes progressive vision loss.

Request a free sample PDF:

Market scope of choroideremia treatment

Ratio attribute


Market Size Value in 2022

$3.5 billion

Revenue forecast in 2031

$5.5 billion



Base year for the estimate


Forecast period

from 2023 to 2031

Historical year


Segments covered

Type and Region

Regional scope

North America, Europe, Asia Pacific, Latin America, the Middle East and Africa

Choroideremia primarily affects males and is characterized by degeneration of the choroid, retina, and retinal pigment epithelium, leading to vision impairment and eventually blindness. The choroideremia treatment market is being driven by factors such as growing awareness and diagnosis of the condition, advances in gene therapy and genetic research, and a growing focus on precision medicine.

Choroideremia Treatment market dynamics are influenced by various factors. First, the growing prevalence of choroideremia and growing awareness among patients and healthcare professionals are driving the growth of the market. Furthermore, advances in gene therapy technologies, such as adeno-associated virus (AAV) vectors, have opened up new avenues for potential treatments, leading to increased research and development in the field.

Furthermore, the strong emphasis on precision medicine and personalized therapies has spurred the development of targeted treatments for specific genetic mutations associated with choroideremia. However, the high cost of treatment, limited access to specialized health centers offering these therapies, and stringent regulatory requirements for gene therapies pose challenges to market growth. Despite these challenges, the choroideremia treatment market is expected to see steady growth as stakeholders strive to improve treatment options, expand patient access, and advance understanding of this rare genetic eye disease .

Recent Development in Choroideremia Treatment Market:

  • In June 2021, the first patient in the Phase 1 clinical study of 4D-110, a Roche-licensed product candidate, delivered via a single intravitreal injection for choroideremia, was administered, according to 4D Molecular Therapeutics, a leading clinical phase in the development precisely guided AAV gene drugs based on directed evolution. The hereditary retinal disease known as choroideremia, which causes blindness and is now incurable, is X-linked.

Customization request

Competitive landscape

A list of the key players operating in the global choroideremia treatment market includes:

  • 4D molecular therapies

  • Therapeutic spark

  • Bluebird Bio Inc.

  • Biogen Inc.

  • Copernicus Therapeutics, Inc.

Market Segmentation:

Based on type, the global choroideremia treatment market is segmented into topical carbonic anhydrase inhibitors (dorzolamide), gene therapy, lutein supplements, and others.

Gene therapy dominated the market with the largest share of revenue. Gene therapy is a cost-effective treatment approach for choroideremia, a rare genetic disease that causes progressive vision loss.

The North American region dominates the market with the largest revenue share, thanks to numerous clinical centers specializing in the diagnosis and treatment of choroideremia.

Report coverage

Global market research on Choroideremia Treatment Market was conducted in depth by Growth Plus Reports. We looked at key market characteristics, noteworthy investment prospects, regional growth trends, 10-year revenue projections, rival market participants, and mergers and acquisitions.

Table of contents


    1. Market ecosystem

    2. Chronology under review

      1. Historic Years 2021

      2. Base year 2022

      3. Forecast years from 2023 to 2031

    3. Currency used in the report


    1. Research approach

    2. Data collection methodology

    3. Data origin

      1. Secondary sources

      2. Primary sources

    4. Approach to market estimation

      1. Bottom up

      2. From top to bottom

    5. Market prediction model

    6. Limitations and assumptions


    1. Current market trends (COVID-19 perspective)

    2. Key players and competitive positioning (2022)

    3. Regulatory landscape


    1. Drivers

    2. Restrictions/Challenges

    3. Opportunity


    1. Topical carbonic anhydrase inhibitor (dorzolamide)

    2. Gene therapy

    3. Lutein supplements

    4. Others


Buy this premium research report:


  • Powered with hours of free analysis and expert interviews with every report

  • Comprehensive quantitative and qualitative insights at the segment and sub-segment level

  • Covid 19 impacts trends and perspectives

  • Granular insights at global/regional/country level

  • In-depth insights into market dynamics (drivers, constraints, opportunities) and the business environment

  • Global coverage of the competitive landscape

  • Winning imperatives

  • Comprehensive coverage of the “strategic developments” recorded by the main market players.


  • Distributor landscape assessment

  • Pricing intelligence

  • Evaluation of the customer base

  • Analysis of investments and initiatives

  • “Company profile” of the main players

Schedule a call with our analyst:

Visit our Report Store at –

Browse the latest health reports:

Glucose-raising agents market by products (glucagon, diazoxide), indication (hypoglycemia, insulinoma), route of administration (oral, parenteral), distribution channel (hospital pharmacies, retail pharmacies), global outlook and forecast 2023-2031

Ergocalciferol market by application (hypoparathyroidism, rickets), route of administration (oral, injectable), distribution channel (hospital pharmacies, retail pharmacies) Global Outlook and Forecasts 2023-2031

Leptin Therapeutic Market by Application (Obesity, Diabetes), Type (Recombinant Leptin, Leptin Receptor Agonists), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) Global Outlook and Forecast 2023-2031

ABCA4 Therapeutic market for retinopathy by drug type (anti-VEGF drugs, LBS-008), age group (children, adults), distribution channel (hospital pharmacy, retail pharmacy) global outlook and forecast 2023-2031

Tocolytic agents market by drug class (magnesium sulfate, betamimetics), route of administration (oral, parenteral) global outlook and forecast 2023-2031

Who we are:

Growth Plus Reports is part of GRG Health, a global health knowledge services company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

The Growth Plus service portfolio draws on our core capabilities in secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable and game-changing solutions that prepare them for future growth and success .

We were awarded by the prestigious CEO magazine as “Most Innovative Healthcare Market Research Firm 2020.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web:

#Choroideremia #Treatment #Market #Worth #Billion #Growth #Reports

By Admin

Leave a Reply

Your email address will not be published. Required fields are marked *